BMS 954561

Drug Profile

BMS 954561

Alternative Names: BMS-954561

Latest Information Update: 28 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Analgesics
  • Mechanism of Action GABA receptor modulators; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Postherpetic neuralgia

Most Recent Events

  • 25 Oct 2011 Bristol-Myers Squibb completes enrolment in its phase II trial for Postherpetic neuralgia in US and France (NCT01305538)
  • 28 Apr 2011 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
  • 07 Apr 2011 Phase-II clinical trials in Postherpetic neuralgia in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top